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SUMMARY 
 
1. The effectiveness of a selective endothelin receptor-A (ET-A) antagonist, A-
127722 (approximately 10 mg kg-1 day-1 as 200 mg kg-1 powdered food), to reverse 
existing cardiac remodelling and prevent further remodelling was tested in 
deoxycorticosterone acetate (DOCA)-salt hypertensive rats.   
2. Uninephrectomised rats (UNX) administered DOCA (25mg every 4th day sc) and 
1% NaCl in drinking water for 28 days developed hypertension (systolic BP: UNX 
128±6, DOCA-salt 182±5* mmHg; *P<0.05 vs UNX), left ventricular hypertrophy 
(UNX 1.99±0.06, DOCA-salt 3.30±0.08* mg/kg body wt), decreased left ventricular 
internal diameter (UNX 6.69±0.18, DOCA-salt 5.51±0.37* mm), an increased left 
ventricular monocyte/macrophage infiltration together with an increased interstitial 
collagen from 2.7±0.3 to 11.7±1.3%, increased passive diastolic stiffness (UNX 
21.1±0.5, DOCA-salt 30.1±1.3*), prolongation of the action potential duration at 20% 
and 90% of repolarization (APD20 – UNX 6.8±1.1, DOCA-salt 10.1±1.5* msec; 
APD90 – UNX 34.4±3.5, DOCA-salt 64.3±10.4* msec) and vascular dysfunction (2.6 
fold decrease in maximal contractile response to noradrenaline, 3.5 fold decrease in 
maximal relaxation response to acetylcholine).  
3. Administration of A-127722 for 14 days starting 14 days after surgery attenuated 
the increases in systolic blood pressure (150±6** mmHg, **P<0.05 vs DOCA-salt), 
left ventricular wet weight (2.65±0.06** mg/kg body wt) and internal diameter 
(6.39±0.31** mm), prevented left ventricular monocyte/macrophage accumulation, 
attenuated the increased left ventricular interstitial collagen (7.6±1.3%**), reversed 
the increased passive diastolic stiffness (22.1±1.2**), attenuated the action potential 
duration prolongation (APD20 – 7.6±1.4**, APD90 – 41.5±6.9** msec) and 
normalized changes in vascular function.  
4. ET-A receptor antagonism both reverses and prevents the cardiac and vascular 
remodelling in DOCA-salt hypertension and improves cardiovascular function.   
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INTRODUCTION 
 
Endothelin (ET)-1, a 21-amino acid peptide released by endothelial cells, is a potent 
vasoconstrictor that may play a role in the pathogenesis of cardiovascular diseases as 
diverse as hypertension, chronic heart failure, ischaemic heart disease, atherosclerosis 
and chronic renal failure (Touyz & Schiffrin, 2003; Masaki, 2004). ET-1 activates 
ET-A and ET-B receptors; non-selective endothelin receptor antagonists such as 
bosentan attenuated left ventricular remodelling and improved survival in rats with 
coronary artery ligation (Mulder et al., 1997). However, early intervention with the 
high affinity non-selective ET receptor antagonist, SB 209670, promoted left 
ventricular dilatation without altering infarct size or collagen composition (Øie et al., 
2002). Using the same model, treatment with the selective ET-A antagonist, LU 
135252 (30 mg kg-1 day-1), for 9 months improved cardiac function measured by 
echocardiography and decreased left ventricular collagen density but did not improve 
long-term survival (Mulder et al., 2002).  
 
These potential therapeutic benefits of endothelin receptor antagonists were defined 
using rat models of cardiovascular disease, in particular the coronary artery ligation 
model of myocardial infarction and heart failure. Other studies with endothelin 
receptor antagonists have used the deoxycorticosterone acetate (DOCA)-salt 
hypertensive rat. These rats develop hypertension, cardiac hypertrophy and fibrosis 
together with over-expression of endothelin by vascular cells and cardiac endothelial 
cells suggesting that endothelin plays an important role in these structural and 
functional changes (Schiffrin, 2001). In this model, administration of the ET-A 
receptor selective antagonist, A-127722 (30 mg kg-1 day-1), as a prevention protocol 
produced a small decrease in blood pressure with no change in heart weight but 
normalised procollagen expression and prevention of cardiac collagen deposition 
(Ammarguellat et al., 2001). Further, the increase in fibronectin deposition, matrix 
metalloproteinase activity and upregulation of inflammatory mediators was reduced 
following ET-A receptor antagonism with BMS 182874 (40 mg kg-1 day-1), another 
selective ET-A receptor antagonist (Ammarguellat et al., 2002). This ET-A receptor 
selective antagonist reduced cardiac macrophage content and decreased expression of 
cell adhesion molecules in DOCA-salt hypertensive rats (Callera et al., 2004). 
DOCA-salt hypertensive rats also developed prolongation of the action potential 
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duration (Momtaz et al., 1996); endothelin produced similar prolongation (Yorikane 
et al., 1991) that was blocked by the selective ET-A receptor antagonist, BQ-123 
(Garjani et al., 1995). Endothelial dysfunction developed in DOCA-salt hypertensive 
rats and was prevented by administration of apocynin, an inhibitor of NADPH 
oxidase (Beswick et al., 2001) or the antioxidant, sesamin (Nakano et al., 2003).  
 
Increases in reactive oxygen species, especially superoxide produced by NADPH 
oxidase, may underlie the development of hypertension and cardiovascular 
remodelling in DOCA-salt rats (Beswick et al., 2001; Li et al., 2003). Reactive 
oxygen species can initiate free radical chain reactions resulting in membrane and cell 
damage; this has been proposed as the cause of cardiovascular damage (Sawyer et al., 
2002). The major source of superoxide production in the vasculature is NADPH 
oxidase (Li & Shah, 2004). The most likely mechanism for NADPH oxidase 
activation in DOCA-salt hypertensive rats is an increased endothelin-1 concentration 
acting through ET-A receptors since selective blockade of ET-A receptors reduced 
arterial superoxide formation and improved structure and function (Callera et al., 
2003; Li et al., 2003; Pu et al., 2003).  
 
This study has used a reversal protocol (oral administration of A-127722 for 2 weeks 
started 2 weeks after initiation of DOCA-salt hypertension) to determine whether 
antagonism of ET-A receptors reverses existing changes and possibly prevents further 
cardiovascular remodelling, thus improving cardiovascular function. We have used 
echocardiography to define cardiac function in vivo and the isolated Langendorff 
heart to define function ex vivo. Single cell microelectrode studies on isolated left 
ventricular papillary muscles were used to determine changes in cardiac action 
potentials. Isolated thoracic aortic rings were used to examine endothelial dysfunction 
in DOCA-salt vessels. Collagen deposition was defined using laser confocal 
microscopy of picrosirius red-stained slices.  
 
 
METHODS 
 
 4
DOCA-salt hypertensive rats 
Male Wistar rats (8-10 weeks old) were obtained from the Central Animal Breeding 
House of The University of Queensland. All experimental protocols were approved 
by the Animal Experimentation Ethics Committee of The University of Queensland 
under the guidelines of the National Medical and Health Research Council of 
Australia. Rats were fed pelleted rat chow and were housed in 12-hour light/dark 
conditions. Uninephrectomy was performed on all treated rats. The rats were 
anaesthetised with tiletamine (25 mg kg-1 ip) and zolazepam (25 mg kg-1 ip)(Zoletil®) 
together with xylazine (10 mg kg-1 ip) (Rompun®); a lateral abdominal incision was 
used to access the kidneys, and the left renal vessels and ureter were ligated. The left 
kidney was removed and weighed and the incision site sutured. Uninephrectomized 
rats were given either no further treatment (UNX rats) or 1% NaCl in the drinking 
water with subcutaneous injections of deoxycorticosterone acetate (DOCA; 25mg in 
0.4ml dimethylformamide every fourth day) (DOCA-salt rats)(Dallemagne et al., 
2000). Experiments were performed 14 or 28 days after surgery. After 14 days, rats 
were given A-127722 (200 mg kg-1 powdered food) for a further 14 days.   
 
Assessment of physiological parameters 
Food and water intake and body weights were measured daily for all rats. Systolic 
blood pressure and heart rate were measured in a subgroup of rats lightly 
anaesthetised with Zoletil® (tiletamine 15mg kg-1 ip with zolazepam 15mg kg-1 ip) 
using a tail pulse transducer (MLT1010) and an inflatable tail cuff with a Capto 
SP844 physiological pressure transducer (MLT844/D) connected to a PowerLab data 
acquisition unit (ADInstruments, Sydney, Australia). Rats were killed with 
pentobarbitone (200 mg kg-1 ip). Blood was taken from the abdominal vena cava, 
centrifuged and the plasma frozen.  
 
Echocardiography 
Serial, in vivo left parasternal and left apical echocardiographic images of rats were 
obtained using the Hewlett Packard Sonos 5500 (12MHz frequency fetal transducer) 
at an image depth of 3 cm using two focal zones (Brown et al., 2002). Rats were 
anaesthetised with Zoletil® (tiletamine 25mg kg-1 ip with zolazepam 25mg kg-1 ip) 
together with Rompun® (xylazine 10mg kg-1 ip) which produces general anaesthesia 
in rats for 2-3 hours. Left ventricular M-mode measurements at the level of the 
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papillary muscles included left ventricular end-diastolic dimensions, left ventricular 
end-systolic dimensions, interventricular septum and posterior wall thicknesses and 
fractional shortening. Cardiac output, ejection fraction and left ventricular mass were 
derived from these values (Litwin et al., 1994). Pulsed-wave Doppler analyses of 
mitral valve inflows were used as estimates of diastolic function.   
 
Isolated heart preparations 
The non-recirculating Langendorff heart preparation was used for isolated myocardial 
experiments (Brown et al., 1999). Briefly, rats were anaesthetised with 
pentobarbitone sodium (100 mg kg-1 ip). The right leg femoral vein was exposed and 
heparin (1000 IU) administered as an intravenous injection. The hearts were rapidly 
excised and placed in ice-cold modified Krebs-Henseleit solution, the aorta isolated 
and cannulated via the dorsal root. Retrograde perfusion was initiated at constant 
pressure (100 cm H2O) with modified Krebs-Henseleit buffer containing (in mM): 
NaCl 119.1, KCl 4.75, MgSO4 1.19, KH2PO4 1.19, NaHCO3 25.0, glucose 11.0 and 
CaCl2 2.16 maintained at 37°C and bubbled with 95% O2 and 5% CO2. A latex 
balloon catheter was inserted into the left ventricle for measurement of isovolumic 
left ventricular function via connection to a Capto SP844 physiological pressure 
transducer (MLT844/D) linked to a PowerLab recording system. Hearts were paced at 
250bpm by attaching two electrodes to the surface of the right atria. End diastolic 
pressure was initially set to 5 mmHg by balloon inflation and all hearts received an 
equilibration period of approximately 25 minutes. End-diastolic pressure was 
measured for 3 minutes at 5mmHg increments beginning at 0mmHg up to a 
maximum of 30mmHg. Measurements of diastolic pressure and systolic pressure were 
made after 2 minutes of each 3 minute recording for further calculation of diastolic 
stiffness and left ventricular developed pressure. Myocardial diastolic stiffness was 
defined by the stiffness constant (k, dimensionless) that is the slope of the linear 
relation between the tangent elastic modulus (E, dyne cm-2) and stress (σ, dyne cm-
2)(Brown et al., 1999). To assess contractile function, maximal +dP/dt values were 
calculated at a diastolic pressure of 10 mmHg.  At the end of the experiment, the atria 
were removed and the weight of the ventricles plus septum was recorded. 
 
Microelectrode studies on isolated left ventricular papillary muscles 
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Rats were anaesthetised by CO2 inhalation and then euthanased by exsanguination. 
The thorax was opened quickly and the heart was removed. The left ventricular 
papillary muscles were quickly dissected in cold Tyrode physiological salt solution 
(in mM: NaCl 136.9, KCl 5.4, MgCl2.H2O 1.0, NaH2PO4.2H2O 0.4, NaHCO3 22.6, 
CaCl2.2H2O 1.8, glucose 5.5, ascorbic acid 0.3, Na2EDTA 0.05) bubbled with 95% O2 
and 5% CO2. A stainless steel hook was placed in one end of the papillary muscle. 
The muscle was placed in a 1.0 mL experimental chamber continuously perfused with 
gassed warm Tyrode solution at 3 mL min-1 (35±0.5°C) and was fixed at the other end 
with a small stainless steel pin embedded into a rubber base. The hook was attached 
to a modified sensor element (SensoNor AE801) connected to an amplifier (World 
Precision Instruments. TBM-4). The muscle was slowly stretched to maximum 
preload over one minute. Contractions were induced by field stimulation (Grass SD-
9) via electrodes on either side of the muscle (stimulation frequency 1 Hz, pulse width 
0.5 msec; stimulus strength 20% above threshold).  
 
After maximum preload was attained, the muscle was allowed to equilibrate for a 
further 45 min before impalement with a glass microelectrode (World Precision 
Instruments, filamented borosilicate glass, outer diameter 1.5 mm) that had a tip 
resistance of 5-15 mΩ when filled with 3 M KCl. The reference electrode was an 
Ag/AgCl electrode. A Cyto 721 electrometer  (World Precision Instruments) was used 
to record bioelectrical activity. All signals were recorded via a PowerLab 4S data 
acquisition unit (ADInstruments, Sydney, Australia). Preparations were accepted that 
had a stable resting potential more negative than -60 mV. Continual impalement 
throughout an experiment was not always possible, however, if displacement 
occurred, then the results of a subsequent impalement were accepted provided the 
data fitted the criteria described above. 
 
Isolated thoracic aortic rings 
Thoracic aortic rings (approximately 4 mm in length) were suspended with a resting 
tension of 10 mN (Brown et al, 1991). Cumulative concentration-response curves 
were performed for noradrenaline and either acetylcholine or sodium nitroprusside in 
the presence of a submaximal contraction to noradrenaline. Maximal contraction was 
recorded as that produced by addition of isotonic potassium chloride (100 mM). 
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Collagen distribution by picrosirius red staining and laser confocal microscopy 
All experimental animals had the major organs removed and weighed. From the 
organs removed, the left ventricle and septum underwent histological analysis. 
Tissues were initially fixed for three days in Telly’s Fixative (100ml of 70% ethanol, 
5ml of glacial acetic acid and 10ml of 40% formaldehyde) and then transferred into a 
pre-stain/fixative known as Modified Bouin’s Fluid (85ml of saturated picric acid, 
5ml glacial acetic acid and 10ml of 40% formaldehyde) for two days. The samples 
were then dehydrated and embedded in paraffin wax. Thick sections (15μm) were cut 
and placed on glass slides coated with Mayer’s albumin solution (1g powdered egg 
albumin, 50ml glycerol, 50ml distilled water), left to air dry for two days and then 
heated in an oven at 56°C for one hour. Phosphomolybdic acid (0.2% in distilled 
water, 5 minutes) was then applied to reduce non-specific binding of the stain to the 
section and then washed in distilled water. The collagen-selective picrosirius red stain 
(0.1% sirius red F3BA in saturated picric acid) was then used and allowed to incubate 
for 90 minutes. The sections were then washed, dehydrated and mounted in Depex 
with a coverslip. Image analysis of the stained sections took place on the Laser 
Scanning Confocal Microscope (BioRad MRC-1024 – Rhodamine/Texas red filter, 
568nm, emission 609 DF 32 by green excitation). Randomly assigned slides and 
sections were scanned representing the perivascular areas of the left ventricle. The 
images were taken with an objective lens of 40x magnification and analysed for pixel 
intensity in a specified area of the section. This data was compiled by a software 
image-rendering program (IA-IP-Lab, Scanalytics Inc Australia). 
 
Immunofluorescence 
For immunostaining, 5 μm thick sections were dewaxed then antigen retrieval carried 
out by microwaving tissue sections in 0.01M citrate buffer for 15 minutes followed by 
pepsin digestion (0.05M) for a further 15 minutes at 37°C. Samples were then 
incubated for 20 minutes at room temperature in blocking solution (PBS containing 
5% sheep serum and 1% bovine serum albumin) before application of primary 
antibodies for rat macrophages (ED1; Serotec mouse anti-rat ED1 diluted 1:15) or α-
smooth muscle actin (1A4; Sigma; diluted 1:400) and incubation overnight at 4°C. 
Omission of primary antibodies, and staining with an irrelevant mouse 
immunoglobulin of the same isotype, served as negative controls. Following PBS 
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washes, samples were incubated with IgG-fluorescein conjugated secondary antibody 
(Chemicon; dilution of 1:200). Sections were counterstained with propidium iodide, 
mounted with gelvatol (polyvinyl alcohol/glycerol) mounting medium containing n-
propyl gallate (5 mg ml-1) as an anti-fade agent and visualised with a Biorad MRC-
1024 confocal laser-scanning microscope using an objective lens of 40x 
magnification. A zero to four grading scale was used to classify the extent of ED 1 
positive monocyte/macrophage infiltration in the left ventricle. 0 = no 
monocyte/macrophages present; 1 = low levels of singular monocyte/macrophages 
located throughout the left ventricle; 2 = moderate numbers of 
monocyte/macrophages located throughout the left ventricle; 3 = large numbers of 
monocyte/macrophages located in groups throughout the left ventricle; 4 = large 
numbers of monocyte/macrophages located as groups throughout the left ventricle 
and scar sites, and associated directly with areas of fibrosis. α-SMA was qualitatively 
assessed for spatial location in the left ventricle. 
 
Data analysis 
All results are given as mean ± SEM. The negative log EC50 of the increase in force 
of contraction in mN was determined from the concentration giving half-maximal 
responses in individual concentration-response curves. These results were analyzed 
by two-way analysis of variance followed by the Duncan test to determine differences 
between treatment groups and by paired or unpaired t-tests as appropriate; p<0.05 was 
considered significant. 
 
Drugs 
Deoxycorticosterone acetate, heparin, noradrenaline, acetylcholine and sodium 
nitroprusside were purchased from Sigma Chemical Company, St Louis, MO, USA. 
A-127722 (2(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-[[(dibutyl amino) 
carbonyl]methyl]-pyrrolidine-3-carboxylic acid) was provided by Abbott 
Pharmaceuticals, USA and thoroughly mixed with ground rat food pellets to a final 
concentration of 200 mg kg-1. Noradrenaline, acetylcholine and sodium nitroprusside 
were dissolved in distilled water; deoxycorticosterone acetate was dissolved in 
dimethylformamide with mild heating. 
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 RESULTS 
 
DOCA-salt hypertensive rats showed an increased water intake (Figure 1) but 
decreased body weight (Figure 2). Administration of A-127722 for 14 days starting 
14 days after induction of hypertension failed to alter water intake (Figure 1), 
however the final body weights were significantly improved (Figure 2). Intake of A-
127722 calculated from daily food intake was not significantly different between the 
treated groups (UNX + A-127722, 8.9±0.7; DOCA-salt + A-127722, 10.7±0.7 mg kg-
1 day-1) (Figure 3). Systolic blood pressure increased during DOCA-salt treatment 
while treatment with A-127722 prevented further increases in blood pressure during 
the last 14 days (Table 1). 
 
DOCA-salt rats showed an increasing degree of left ventricular hypertrophy during 
the study period as evidenced by left ventricular wet weights relative to body weight 
and left ventricular mass derived from echocardiography (Table 1). This increase in 
left ventricular mass was supported by a decrease in left ventricular internal diameter 
indicating concentric cardiac hypertrophy (Table 1). Treatment from day 14 with A-
127722 prevented further increases in these parameters (Table 1). In contrast, the 
increased weights of the right ventricle and remnant kidney were not affected by A-
127722 treatment (Table 1). Thoracic aortic wall thicknesses and aortic blood flow 
velocities were increased by DOCA-salt treatment; A-127722 treatment prevented 
and reversed these changes (Table 1). DOCA-salt rats showed increased left 
ventricular perivascular and interstitial collagen following 2 weeks of hypertension 
with further increases occurring 4 weeks after induction (Table 1). Treatment from 
day 14 with A-127722 prevented this further increase (Table 1). As a functional 
measure of left ventricular remodelling, diastolic stiffness obtained from the isolated 
Langendorff heart preparation was significantly increased in the DOCA-salt 
hypertensive rat after 2 weeks and further increased after 4 weeks. This increase in 
cardiac stiffness was completely prevented and reversed by A-127722 treatment for 
the last 14 days (Table 1). ED1-positive monocyte/macrophages were found in the left 
ventricle of UNX rats in low numbers; there was a marked increase in DOCA-salt rats 
(figure 4). These cells were usually found as clusters of cells located at scar sites and 
throughout the interstitium. Treatment with A-127722 significantly reduced 
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macrophage infiltration within scar sites and almost completely prevented 
macrophage infiltration into the left ventricular interstitium of DOCA-salt rats.  
 
Echocardiographic assessment showed that A-127722 failed to alter the increased 
ejection fraction and decreased cardiac output observed in DOCA-salt hypertensive 
rats (Table 1). The lack of significant improvement in systolic function by A-127722 
in vivo was supported by contractility studies on isolated Langendorff hearts. DOCA-
salt hearts showed a decreased +dP/dt that was unaltered by A-127722 treatment 
(Table 1). Diastolic cardiac function as defined by the E/A (early/atrial) mitral valve 
flow ratio showed a restrictive pattern that was prevented by treatment with A-127722 
(Table 1). 
 
Left ventricular remodelling in DOCA-salt hearts resulted in a significant increase in 
action potential duration at 20% and 90% of repolarisation after 2 and 4 weeks. This 
was partially attenuated by A-127722 at 20% of repolarisation and significantly 
prevented and reversed at 50% and 90% of repolarisation (Figure 5). 
 
Isolated thoracic aortic rings from DOCA-salt rats showed a decreased absolute 
maximal contractile responses to noradrenaline and potassium chloride with marked 
endothelial dysfunction shown as markedly reduced relaxation responses to 
acetylcholine but unchanged relaxant responses to sodium nitroprusside (Figure 6). 
Treatment with A-127722 normalised these decreased responses (Figure 6). 
 
 
DISCUSSION 
 
Hypertension, hypertrophy, activation of inflammatory processes, cardiac fibrosis, 
increased cardiac stiffness, decreased cardiac function, action potential prolongation 
and endothelial dysfunction have been well-described following induction of DOCA-
salt hypertension in rats (Ammarguellat et al., 2001, 2002; Brown et al., 1999; Callera 
et al., 2004; Mirkovic et al., 2002; Momtaz et al., 1996; Nakano et al., 2003). An 
increased endothelin-1 concentration acting through ET-A receptors has been shown 
to be a major cause of the hypertrophy and fibrosis since these changes could be 
prevented by administration of the selective ET-A receptor antagonists, A-127722, 
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BMS 182874 and LU 135252 (Ammarguellat et al., 2001, 2002; Callera et al., 2004; 
Mulder et al., 2002). Since A-127722 decreased monocyte/macrophage infiltration, 
interstitial and perivascular collagen deposition, cardiac stiffness, action potential 
prolongation and endothelial dysfunction in our study, our first major conclusion is 
that these changes in the DOCA-salt hypertensive rat are mediated predominantly by 
ET-A receptor activation. 
 
In contrast to these consistent responses reported with selective ET-A receptor 
antagonists, the non-selective endothelin receptor antagonists, bosentan and SB 
209670, either prevent or have no effect on cardiovascular remodelling (Mulder et al., 
1997; Øie et al., 2002). ET-B receptor activation may be cardioprotective, for 
example by limiting the size of the infarct following coronary artery occlusion and 
preventing a reduction in ET-B receptors in the ischaemic zone (Crockett et al., 
2004). However, in DOCA-salt hypertensive rats, ET-1 acting through an 
upregulation of ET-B receptors was a potent stimulus for elevation of superoxide 
levels in sympathetic ganglia (Dai et al., 2004). This suggests that selective ET-A 
receptor antagonism is a better therapeutic intervention than non-selective ET 
receptor antagonism.  
 
 
In the DOCA-salt hypertensive rat, the key mechanism for the induction of cardiac 
and vascular damage by endothelin-1 is likely to be the augmentation of vascular and 
cardiac superoxide production by NADPH oxidase by activation of ET-A receptors 
(Callera et al., 2003; Li et al., 2003; Pu et al., 2003). Selective blockade of ET-A 
receptors reduced arterial superoxide formation (Callera et al., 2003; Li et al., 2003) 
that was associated with improved vascular reactivity to acetylcholine (Callera et al., 
2003) and decreased hypertrophic remodelling and extracellular matrix deposition (Pu 
et al., 2003). Extracellular matrix deposition is strongly linked to an increased 
ventricular stiffness (Weber et al., 1993). In addition, ET-1 induced cyclo-oxygenase-
2 upregulation in rat endothelial cells that may contribute to superoxide generation; 
this upregulation was inhibited by the non-selective ET receptor antagonist, TAK044 
(Sugiyama et al., 2004). ET-1-induced signalling events in vascular smooth muscle 
cells have been shown to critically depend on reactive oxygen species (Daou & 
Srivastava, 2004). Further, both hypertension and vascular production of superoxide 
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were attenuated by the selective ET-A receptor antagonist, ABT-627 (5 mg kg-1 day-1) 
in ET-B receptor-deficient rats (Elmarakby et al., 2004). Suppression of superoxide 
formation by sesamin also markedly decreased the impaired vasodilator responses to 
acetylcholine in DOCA-salt hypertensive rats (Nakano et al., 2003). Thus, oxidative 
stress induced by endothelin-1 via ET-A receptors is likely to play an important role 
in both cardiac and endothelial dysfunction in the DOCA-salt hypertensive rat.  
 
The same mechanism may be involved in the electrical remodelling in the DOCA-salt 
hypertensive rat heart. Reactive oxygen species such as superoxide mediated the 
prolongation of the action potential duration of the cytokine, tissue necrosis factor-α, 
by a functional depression of the delayed rectifier K+-current (Wang et al., 2004). 
Endothelin-1 increased action potential duration in cardiac myocytes (Yorikane et al., 
1991), probably due to an increased Ca2+ mobilisation and decreased K+ channel 
currents (Washizuka et al., 1997). Chronic treatment with the selective ET-A receptor 
antagonist, TA-0201 (approximately 1.3 mg kg-1 day-1), inhibited electrical 
remodelling including action potential duration prolongation and suppressed 
ventricular arrhythmias in cardiomyopathic hamster hearts (Matsumoto et al., 2002). 
Acute ET-A receptor blockade with BQ-123 (0.4 mg kg-1) reduced the incidence of 
ventricular tachycardia and fibrillation during the first 24 hours after coronary artery 
ligation through a decrease in dispersal of repolarization (Baltogiannis et al., 2005). 
Duru et al. (2001) have discussed the proposed mechanisms and therapeutic potential 
of endothelin antagonists as antiarrhythmic drugs. These results strongly suggest that 
administration of A-127722 as a selective ET-A receptor antagonist in our study 
reversed the prolongation of the action potential duration by suppressing the increased 
superoxide production following activation of ET-A receptors in the DOCA-salt 
hypertensive rat. 
 
The second major conclusion of this study is that selective ET-A receptor antagonism 
can reverse some of the existing damage to the heart and blood vessels in addition to 
preventing further damage. Cardiac and vascular damage in the DOCA-salt 
hypertensive rat is clearly evident after two weeks and increases in the following two 
weeks. While administration of an ET-A antagonist has been shown to prevent 
cardiovascular damage when given from the initiation of DOCA-salt hypertension, 
our results show that the cardiovascular changes produced in the first two weeks can 
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be reversed by ET-A receptor blockade during the next two weeks. In particular, the 
decreased interstitial collagen should improve both myocardial relaxation and 
contraction while the decreased perivascular collagen should improve nutrient 
distribution and removal of waste products. We have shown previously using a 
similar reversal protocol that the antiinflammatory compound, pirfenidone, reversed 
the cardiovascular changes in DOCA-salt hypertensive rats (Mirkovic et al., 2002) 
and in streptozotocin-diabetic rats (Miric et al., 2001).  
 
Thus, an increased endothelin production is likely to be responsible for the cardiac 
and vascular changes in the DOCA-salt hypertensive rat probably through activation 
of superoxide production by NADPH oxidase. Further, selective blockade of ET-A 
receptors both reverses and prevents these cardiovascular changes and leads to an 
improved cardiac and vascular function.   
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Table 1: Physiological parameters 
 
PARAMETER UNX 
(n=10) 
UNX + A-
127722 
(n=8) 
DOCA-salt 
14 days (n=6) 
DOCA-salt   
28 days 
(n=10) 
DOCA-salt 
 + A-127722 
28 days 
(n=8) 
Whole animal 
Initial body weight (g) 
 
302 ± 4 
 
307 ± 2 
 
305 ± 4 
 
307 ± 5 
 
310 ± 4 
Final body weight (g) 376 ± 11 399 ± 13 325 ± 6 312 ± 8 344 ± 7 
Heart rate (bpm) 390 ± 12 382 ± 19 401 ± 23 397 ± 17 368 ± 20 
Systolic blood pressure 
(mmHg) 
128 ± 6 127 ± 3 158 ± 3* 182 ± 5*# 150 ± 6 ** 
Organ weights 
Left ventricular weight 
(mg/g bwt) 
 
1.99 ± 0.06 
 
2.20 ± 0.05 
 
2.48 ± 0.05* 
 
3.30 ± 0.08*#
 
2.65 ± 0.06**#
Right ventricular weight 
(mg/g bwt) 
0.56 ± 0.02 0.54 ± 0.04 0.56 ± 0.02 0.65 ± 0.03* 0.63 ± 0.03* 
Kidney weight (mg/g bwt) 4.98 ± 0.11 4.65 ± 0.08 7.76 ± 0.33* 10.90 ± 0.40* 10.03 ± 0.55*#
Histology 
Thoracic aortic ring wall 
thickness (μM) 
 
192 ± 7 
 
196 ± 8 
 
236 ± 4* 
 
312 ± 5*#
 
228 ± 3 ** 
Left ventricular perivascular 
collagen fraction (% area) 
27.9 ± 4.4 32.3 ± 3.9 37.8 ± 2.1* 38.9 ± 2.8* 32.7 ± 1.9** 
Left ventricular interstitial 
collagen fraction (% area) 
2.7 ± 0.3 4.2 ± 1.9 6.7 ± 2.4* 11.7 ± 1.3*# 7.6 ± 1.3** 
Kidney interstitial collagen 
fraction (% area) 
22.4 ± 3.6 19.8 ± 3.7 30.9 ± 2.2* 39.1 ± 3.6* 32.4 ± 4.8* 
Function 
Diastolic stiffness 
 
21.1 ± 0.5 
 
22.5 ± 1.0 
 
24.6 ± 1.8* 
 
30.1 ± 1.3*#
 
22.1 ± 1.2** 
Maximum +dP/dT 
(mmHg/sec) 
1790 ± 140 1630 ± 100 1670 ± 80 1380 ± 170*# 1440± 100* 
Minimum –dP/dT 
(mmHg/sec) 
1490 ± 70 1500 ± 130 1500 ± 110 1310 ± 150 1250 ± 110 
Echocardiography 
LVIDd (mm) 
 
6.69 ± 0.18 
 
7.17 ± 0.16 
 
6.29 ± 0.16 
 
5.51 ± 0.37*#
 
6.39 ± 0.31** 
LVPWd (mm) 1.74 ± 0.17 1.78 ± 0.17 1.79 ± 0.07 1.98 ± 0.09 1.85 ± 0.09 
1.88 ± 0.10** E/A (early/atrial) mitral valve 
flow ratio 
1.92 ± 0.02 1.88 ± 0.07 1.82 ± 0.27 1.64 ± 0.10* 
Ejection fraction (%) 83.1 ± 4.4 82.7 ± 5.6 94.6 ± 1.1* 92.7 ± 1.2* 94.8 ± 1.3* 
Cardiac output (ml/min) 75.3 ± 3.6 72.1 ± 6.8 63.9 ± 7.8 53.7 ± 6.7* 58.1 ± 5.3* 
Ascending aorta (m/sec) 0.75 ± 0.08 0.88 ± 0.10 1.12 ± 0.07* 1.23 ± 0.05* 0.98 ± 0.06** 
Left ventricular mass (g) 
(Litwin et al, 1994) 
0.76 ± 0.04 0.85 ± 0.09 0.75 ± 0.03 1.36 ± 0.09*# 0.99 ± 0.08**#
 
All values shown represent the mean ± SEM. LVIDd=left ventricular internal 
diameter in diastole; LVPWd=left ventricular posterior wall thickness in diastole. 
Significance - *p < 0.05 vs UNX rats; **p < 0.05 vs DOCA-salt rats. 
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FIGURE 5a 
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FIGURE 5b 
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LEGENDS TO FIGURES 
 
Figure 1: Daily water intake measurements for UNX (ρ, n=21), UNX+A-127722 (ν, 
n=16), DOCA-salt (μ, n=36) and DOCA-salt+A-127722 (λ, n=20) treated rats; 
*p<0.05 vs UNX rats. 
 
Figure 2: Daily body weight measurements for UNX (ρ, n=21), UNX+A-127722 (ν, 
n=16), DOCA-salt (μ, n=36) and DOCA-salt+A-127722 (λ, n=20) treated rats; 
*p<0.05 vs UNX rats. 
 
Figure 3: Daily A-127722 dose for UNX+A-127722 (ν, n=16) and DOCA-salt+A-
127722 (λ, n=20). 
 
Figure 4: Immunohistochemical analysis of ED1 cells in left ventricular interstitium; 
*p<0.05 vs UNX rats; **p<0.05 vs DOCA-salt rats.  
 
Figure 5: Representative action potentials (a) and action potential durations (b) at 20, 
50 and 90% repolarization in isolated papillary muscles from UNX (ρ, n=8), 
UNX+A-127722 (ν, n=6), DOCA-salt (μ, n=6 at 2 weeks, n=8 at 4 weeks) and 
DOCA-salt+A-127722 (λ, n=8) treated rats; *p<0.05 vs UNX rats, ** p<0.05 vs 
DOCA-salt rats (4 weeks), # p<0.05 vs DOCA-salt rats (2 weeks). 
 
Figure 6: Cumulative concentration-response curves for (a) noradrenaline, (b) 
acetylcholine and (c) sodium nitroprusside in thoracic aortic rings from UNX (ρ, 
n=12), UNX+A-127722 (ν, n=7), DOCA-salt (μ, n=7 at 2 weeks, n=12 at 4 weeks) 
and DOCA-salt+A-127722 (λ, n=8) treated rats; maximal contractile response to 
noradrenaline from UNX (9.9±1.9 mN), UNX+A-127722 (9.4±1.3 mN), DOCA-salt 2 
weeks (8.9±1.3 mN), DOCA-salt 4 weeks (4.7±0.5*# mN), DOCA-salt+A-127722 
(8.8±1.6** mN); maximal contractile response to potassium chloride (100 mM) from 
UNX (13.9±4.2 mN), UNX+A-127722 (15.5±1.6 mN), DOCA-salt 2 weeks (10.5±3.8 
mN), DOCA-salt 4 weeks (5.4±0.6* mN), DOCA-salt+A-127722 (10.1±1.8** mN); 
maximal relaxant response to acetylcholine from UNX (5.2±1.9 mN), UNX+A-
127722 (5.4±0.2 mN), DOCA-salt 2 weeks (2.9±0.8* mN), DOCA-salt 4 weeks 
(1.8±0.4* mN), DOCA-salt+A-127722 (3.9±0.9** mN); maximal relaxant response to 
sodium nitroprusside from UNX (8.3±1.9 mN), UNX+A-127722 (9.1±1.5 mN), 
DOCA-salt 2 weeks (9.2±2.7 mN), DOCA-salt 4 weeks (6.1±1.8 mN), DOCA-salt+A-
127722 (9.9±2.3 mN); *p<0.05 vs UNX rats; **p<0.05 vs DOCA-salt rats, # p<0.05 
vs DOCA-salt rats (2 weeks). 
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